NCT06056830ClinicalTrials.gov
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
Kurz gefasst
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Phase 3383 Teilnehmende gesucht34 Studienzentren3 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT06056830Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert letzte Woche
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 31 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.
How this score is built
- Enrolment25/40
383 participants (target)
- Site count18/25
31 sites
- Country count7/15
3 countries
- Planned duration8/10
Planned over about 33 months
- Sponsor scale2/10
Clarity Pharmaceuticals Ltd has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Erkrankungen
- Prostate Cancer
- Prostatic Neoplasms
Eignung
| Geschlecht | Männlich |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 3 |
| Zuteilung | Nicht zutreffend |
| Interventionsmodell | SINGLE_GROUP |
| Primäres Ziel | DIAGNOSTIC |
| Verblindung | NONE (0) |
| Teilnahme | 383 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Clarity Pharmaceuticals Ltd Sponsor
Studienarme und Interventionen
- 64Cu-SAR-bisPSMAEXPERIMENTAL
200MBq 64Cu-SAR-bisPSMA.
Interventionen
- Arzneimittel 64Cu-SAR-bisPSMA
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
Endpunkte
Primärer Endpunkt
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases
Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.
Zeitrahmen Up to 16 weeks
Sekundärer Endpunkt
Safety and tolerability of 64Cu-SAR-bisPSMA
Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA
Zeitrahmen Up to 16 weeks
Sekundärer Endpunkt
Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers
Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic
Zeitrahmen Up to 16 weeks
Sekundärer Endpunkt
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth
Zeitrahmen Up to 16 weeks
Sekundärer Endpunkt
Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer
Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth
Zeitrahmen Up to 16 weeks
Sekundärer Endpunkt
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching
Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth
Zeitrahmen Up to 16 weeks
Daten
| Startdatum | 21. Dezember 2023 (tatsächlich) |
|---|---|
| Primärer Abschluss | 1. September 2026 (geschätzt) |
| Abschluss | 1. September 2026 (geschätzt) |
| Erstveröffentlichung | 28. September 2023 (tatsächlich) |
| Zuletzt aktualisiert | 11. September 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | September 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
34 Studienzentren rekrutieren
Australia
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Fiona Stanley Hospital | Murdoch | Western Australia | Rekrutiert |
| RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private Hospital | Nedlands | Western Australia | Rekrutiert |
| St. Vincent's Sydney | Sydney | New South Wales | Rekrutiert |
| Princess Alexandra Hospital | Woolloongabba | Queensland | Rekrutiert |
Puerto Rico
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Pan American Center for Oncology Trials, LLC - Ciudadela | San Juan | Rekrutiert |
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Albany Medical College, Department of Urology | Albany | New York | Rekrutiert |
| Urology Austin, PLLC - Research Department | Austin | Texas | Rekrutiert |
| University of Alabama Birmingham Hospital | Birmingham | Alabama | Rekrutiert |
| University of Texas Southwestern Medical Center | Dallas | Texas | Rekrutiert |
| Urology Clinics of North Texas | Dallas | Texas | Rekrutiert |
| Duke University Medical Center | Durham | North Carolina | Rekrutiert |
| NorthShore University Health System, Glenbrook Hospital | Glenview | Illinois | Rekrutiert |
| BAMF Health | Grand Rapids | Michigan | Rekrutiert |
| Corewell Health | Grand Rapids | Michigan | Rekrutiert |
| Indiana University School of Medicine | Indianapolis | Indiana | Rekrutiert |
| Mayo Clinic- Jacksonville | Jacksonville | Florida | Rekrutiert |
| Arkansas Urology Research Center, LLC | Little Rock | Arkansas | Rekrutiert |
| Greater Los Angeles VA Medical Center | Los Angeles | California | Rekrutiert |
| Urology Group of Southern California | Los Angeles | California | Rekrutiert |
| University of Wisconsin | Madison | Wisconsin | Rekrutiert |
| Biogenix Molecular, LLC | Miami | Florida | Rekrutiert |
| Intermountain Health | Murray | Utah | Rekrutiert |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | Rekrutiert |
| Urology Associates of Nashville | Nashville | Tennessee | Rekrutiert |
| Mount Sinai Doctors Urology Faculty Practice | New York | New York | Rekrutiert |
| XCancer Omaha LLC | Omaha | Nebraska | Rekrutiert |
| UC Irvine Health | Orange | California | Rekrutiert |
| Mayo Clinic- Phoenix | Phoenix | Arizona | Rekrutiert |
| Mayo Clinic- Rochester | Rochester | Minnesota | Rekrutiert |
| The Urology Place | San Antonio | Texas | Rekrutiert |
| Oregon Urology | Springfield | Oregon | Rekrutiert |
| Stanford University Medical Center | Stanford | California | Rekrutiert |
| Urologic Specialists | Tulsa | Oklahoma | Rekrutiert |
| Wichita Urology Group | Wichita | Kansas | Rekrutiert |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 11. September 2026
Studienzentrum hinzugefügt
3 sites added (34 total)
3134